The role of association of ADRB2 gene polymorphism with therapeutic response to β2-agonists in children with recurrent bronchial obstruction
Keywords:bronchitis, obstruction, ADRB2 gene, β2-agonists, children
Background. The study of the effect of drugs at the molecular genetic level in the recurrent course of bronchial obstruction (RBО) in children improved the understanding of the pathogenesis of the disease and made it possible to better characterize the reliability of use in therapy. The aim of the study was to assess the clinical significance of the polymorphism of the Arg16Gly loci of the ADRB2 gene with a therapeutic response to β2-agonists in children with RBО of Uzbek ethnicity. Materials and methods. Tested 88 patients aged 6 to 15 years with recurrent bronchial obstruction and bronchial asthma with the polymorphism of the ADRB2 gene loci and determined the effectiveness of salbutamol in these groups of patients. Results. Results of the study of the significance of the polymorphism of the Arg16Gly locus of the ADRB2 gene with a therapeutic response to β2-agonists in children with RBO showed high efficacy of salbutamol in 72.9 % of children, among whom representatives of the A/G and A/A genotypes were found in the largest number. At the same time, the low efficacy of salbutamol was found in the greatest amount in carriers of the mutational genotype G/G of the Arg16Gly locus of the ADRB2 gene. Conclusions. The predictor role of the polymorphic locus rs1042713 (Arg16Gly) was determined in carriers of the unfavorable 46G allele of the G/G genotype of the ADRB2 gene, which was a genetic marker of children’s predisposition to RBO and BA in children. Children with the G/G genotype of the Arg16Gly locus of the ADRB2 gene are at risk for severe RBO and BA in children. Children with RBO carriers (Arg16Gly) of the homozygous G/G genotype have a high incidence of RBO recurrence against the background of ARVI and are at risk of developing BA.
Abaturov OE, Rusakova OA. Prediction of the individual risk of bronchial obstruction in acute bronchitis in infants. Zdorov'e rebenka. 2015;(60):55-60. doi:10.22141/2224-0518.104.22.1685.74956. (in Ukrainian).
Alekseeva OV. Optimization of differential diagnosis of recurrent bronchitis in children. Siberian Medical Journal (Irkutsk). 2013;(2):37-41. (in Russian).
Balabolkin II, Bulgakova VA, Pinelis VG, Tjumenceva ES. Pharmacogenetics and individualized approach to the treatment of bronchial asthma. Bulletin of Siberian Medicine. 2017;16(2):20-31. doi:10.20538/1682-0363-2017-2-20-31. (in Russian).
Voropaev EV, Ruzanov DYu, Osipkina OV, et al. Association of MDR1, ADRB2 and IL-13 gene polymorphisms with development of therapy-resistant bronchial asthma. Health and ecology issues. 2018;(2):50-55. doi:10.51523/2708-6011.2018-15-1-8. (in Russian).
Zakirova UI. Predicting the risk of developing bronchial asthma in children of the Uzbek population. Problems of biology and medicine. 2021;(1):104-107. (in Russian).
Kulikov ES, Ogorodova LM, Frejdin MB., Deev IA, Selivanova PA, Fedosenko SV. Molecular and pharmacogenetic mechanisms of severe bronchial asthma. Vestnik RAMN. 2013;(3):15-23. doi:10.15690/vramn.v68i3.596. (in Russian).
Kytikova OJu, Gvozdenko TA, Antonjuk MV. Modern aspects of prevalence of chronic bronchopulmonary diseases. Bulletin Physiology and Pathology of Respiration. 2017;(64):94-100. doi:10.12737/article_5936346fdfc1f3.32482903. (in Russian).
Liang SQ, Chen XL, Deng JM, et al. Beta-2 adrenergic receptor (ADRB2) gene polymorphisms and the risk of asthma: a meta-analysis of case-control studies. PLoS One. 2014 Aug 11;9(8):e104488. doi:10.1371/journal.pone.0104488.
Livshits LA, Tatsrsky PF, Gorodna OV, et al. Polymorphism of the ADRB2 gene as a factor of hereditary susceptibility to the development of asthma and response to salbutamol therapy. Perinatologiya and pediatriya. 2019;(78):38-45. (in Russian).
Shah NJ, Vinod Kumar S, Gurusamy U, Annan Sudarsan AK, Shewade DG. Effect of ADRB2 (adrenergic receptor β2) gene polymorphisms on the occurrence of asthma and on the response to nebulized salbutamol in South Indian patients with bronchial asthma. J Asthma. 2015 Oct;52(8):755-762. doi:10.3109/02770903.2015.1012589.
How to Cite
This work is licensed under a Creative Commons Attribution 4.0 International License.